Treatment Options for COVID-19: Evidence Review for Promising Candidates
June 28, 2021
Treatment Options for COVID-19: Evidence Review for Promising Candidates
Authored By: Meng Zhu, Mohit Bhandari On Behalf of OrthoEvidence
Since the beginning of the COVID-19 pandemic, the government of the United States (US) has invested over 19 billion US dollars in 7 private pharmaceutical manufacturers in order to promote the development and production of effective vaccines against SARS-CoV-2 infection (US Congressional Budget Office).
So far, vaccines from 3 of the 7 pharmaceutical manufacturers, including Pfizer/BioNTech, Moderna, and Janssen, have been granted the emergency use authorization (EUA) by the US Food and Drug Administration (FDA). These vaccines, along with those used outside the US (e.g., the AstraZeneca vaccine), have prevented hundreds of thousands of SARS-CoV-2 infections all over the world.
On top of the progress made for COVID-19 vaccines, the US government recently turned their eyes to antiviral medicines against SARS-CoV-2. On June 17th, 2021, the US Department of Health and Human Services (HHS) announced....
To view the full content, login to your account,
FREE TRIAL LOGIN Forgot Password?SHARE THIS OE ORIGINAL
Loading...
Join the Conversation
Please Login or Join to leave comments.